Supercharged immune cells take on melanoma that resists standard treatment
NCT ID NCT05629546
First seen Jun 26, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This early-phase trial tests a new combination treatment for people with advanced melanoma that has worsened despite standard immunotherapy. The treatment uses specially trained natural killer cells (either from the patient or a healthy donor) along with two immunotherapy drugs, nivolumab and relatlimab. The goal is to see if this approach is safe and can shrink tumors. The study is currently recruiting 33 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Memory-like natural killer cells (from the patient or a donor) combined with nivolumab and relatlimab
- What this could lead to
- If successful, this could offer a new treatment option for advanced melanoma that has stopped responding to standard immunotherapy.
- What could go wrong
- This is a very early Phase 1 trial with only 33 participants, so safety and effectiveness are not yet known. The approach is complex and may cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Can a new biologic drug shrink advanced melanoma tumors?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers